|  |  |
| --- | --- |
| Name: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ | Date: \_\_\_\_\_\_\_\_\_\_\_\_\_\_ |

Test your Covid-19 Vaccine Knowledge

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 |  |  |  |
|  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  | 3 |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  | 4 |  |  |  |  |  |  |  | 5 |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  | 6 |  |  |  |  | 7 |  |  | 8 |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  | 9 |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  | 10 |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  | 11 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 12 |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | 13 |  |  |  | 14 |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  | 15 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  | 16 |  |  |  |  |  |  |  |  |  |  |  |  |

|  |  |
| --- | --- |
| **Across**  **2.** Effective mitigation measures can lower the basic reproductive rate (R) to an effective transmission \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (noun, sing.)  **4.** The strength by which an antibody binds to complex antigen (noun, sing.)  **9.** Natural bioreactor (noun, sing.)  **11.** The term given to a surrogate lentiviral vector with the SARS-CoV-2 spike protein expressed on its surface (noun, sing.)  **13.** The reason why exising T cells in a host may neutralise SARS-Cov-2 without a previous Covid-19 infection or immunisation (noun, sing.)  **15.** Tthe percentage of negative samples that are reported as negative by an assay (noun, sing.)  **16.** The component of blood that contains antibodies and other proteins, but not clotting factors (noun, sing.) | **Down**  **1.** Cells responsible for immunity to a coronavirus infection (noun, sing.)  **3.** Ingredients used in some vaccine types for a stronger immune response (noun, pl.)  **5.** The term used for percent reactivity for a test's positively or false-negatively reported samples (noun, sing.)  **6.** Groups of apoptotic cells after in vitro SARS-CoV-2 infection and succesful viral replication (noun, pl.)  **7.** Indigenous, native (noun, sing.)  **8.** Ability of a virus to preferentially infect a particular cell or a tissue (noun, sing.)  **10.** Human infectious diseases caused by a pathogen originating from a non-human organism (noun, pl.)  **12.** The protein to which you are assessing antibodies against in an antibody assay (noun, sing.)  **14.** The viral surface protein which is the determinant for coronavirus entry into target cells (noun, sing.) |